XCancer

Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors

Description:

RT01-89Zr is a TF-targeting radiopharmaceutical diagnostic agent. This trial aims to evaluate the safety, biodistribution, dosimetry, and imaging characteristics of RT01-89Zr as a PET/CT tracer in patients with malignant solid tumors that highly express the TF target.

Sponsor:

Primo Biotechnology Co., Ltd

Phase:

Early Phase 1

Contacts:

Jingchun Yu (CONTACT)

ycjwxd1978@jiangnan.edu.cn

0510-68089404

Government Study Link:

NCT07505069 - Click here to see study on

ClinicalTrials.gov

RT01

Isotope(s):
Target(s):
  • Tissue Factor
Ligand Class: Antibodies
Inclusion
  • During the screening period, tumor tissue samples (either archived previously or freshly biopsied) can be provided, with positive target expression of more than 1%;
  • Confirmed as a solid tumor by histopathology or cytology;
  • ECOG Performance Status: 0 or 1;
  • At least one primary or metastatic lesion confirmed by conventional imaging；
Exclusion
  • Those who have received radiopharmaceuticals before administration and whose discontinuation duration does not exceed 5 half-lives;